news 
Johnson & Johnson (JNJ) Stock: Q2 Earnings Top Estimates, Full-Year Outlook Raised
In a remarkable second-quarter earnings report, Johnson & Johnson (JNJ) surpassed expectations and bolstered its full-year forecast. The pharmaceutical giant’s impressive performance highlights the company’s resilience and growth potential across various business lines.
The healthcare behemoth’s adjusted EPS came in at $2.77, surpassing estimates of $2.66. Meanwhile, revenue rose 5.8% year-over-year to a staggering $23.74 billion, exceeding forecasts of $22.8 billion. The company has now lifted its full-year outlook for both sales and earnings.
JNJ’s Q2 adjusted EPS of $2.77 surpassed expectations of $2.66, while reported EPS was $2.29.
Source: coincentral.com
